Seung Hun Park

Seung Hun Park

Auto-generated profile, based on publicly available information

Seung Hun Park

Gordon Center for Medical Imaging Department of Radiology Massachusetts General Hospital and Harvard Medical School Boston MA 02114 USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2022 in Nanomedicine
Verified
Journal Article
Closed access
GJGregory Jones
Gregory Jones
LZLingxue Zeng
Lingxue Zeng
WSWesley R Stiles
Wesley R Stiles
SPSeung Hun Park
Seung Hun Park
Homan KangHoman Kang
Homan Kang
JKJonghan Kim
Jonghan Kim
Aim: To characterize the pharmacokinetics of deferoxamine-conjugated nanoparticles (DFO-NPs), a novel nanochelator for removing excess iron. Materials & methods: The pharmacokinetics of DFO-NPs wer... Plain language summary Iron is an essential metal nutrient, but excess iron produces toxic effects that damage multiple organs including the heart, liver and pancreas. Deferoxamine (DFO) is a US FD...

4 September 2024 in Advanced Science
Verified
Journal Article
Open access
ARAthira Raveendran
Athira Raveendran
JSJinhui Ser
Jinhui Ser
SPSeung Hun Park
Seung Hun Park
PJPaul Jang
Paul Jang
Hak Soo ChoiHak Soo Choi
Hak Soo Choi
HCHoonsung Cho
Hoonsung Cho
Autodynamic cancer therapy possesses tremendous potential for enhancing therapeutic efficacy by initiating the treatment process autonomously within targeted cells. However, challenges related to biocompatibility and targeted delivery have hindered its clinical translation owing to the induction of adverse effects and cytotoxicity in healthy cells. In this study, a novel approach for auto‐initiated dynamic therapy by conjugating zwitterionic near‐infrared fluorophores to a cell‐penetrating peptide is proposed. This enables efficient cellular uptake and specific targeting of therapy to desired cells while avoiding off‐target uptake. The zwitterionic bioconjugate causes cancer‐specific toxicity following its internalization into the targeted cells, triggered by specific intracellular conditions in lysosomes. This innovative approach enables selective targeting of lysosomes in malignant cells while minimizing cytotoxic effects on normal cells. By targeting lysosomes, the method overcomes inherent risks and side effects associated with conventional cancer treatments, offering a selective and effective approach to cancer therapy.